Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLUOTHANE vs ETOMIDATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
Induction and maintenance of general anesthesia,Off-label: Use for status asthmaticus (rarely)
Induction of general anesthesia,Procedural sedation (off-label),Rapid sequence intubation (off-label)
Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
Terminal elimination half-life is biphasic: initial 2-5 minutes (rapid redistribution), terminal 15-20 hours for trace amounts in adipose tissue due to slow release; contextually, emergence from anesthesia occurs within minutes.
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Hepatic metabolism via cytochrome P450 enzymes (CYP2E1 major, CYP2A6 minor) to trifluoroacetic acid, chloride, and bromide ions; reductive metabolism under hypoxic conditions produces potentially hepatotoxic intermediates.
Etomidate is extensively metabolized in the liver via hydrolysis of the ester side chain by hepatic esterases to its principal metabolite, etomidate carboxylic acid. A minor metabolite is formed via N-demethylation. Metabolites are inactive.
Primarily exhaled unchanged via the lungs; negligible renal (0.5% as metabolites) and fecal elimination.
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
~40-50% bound to albumin.
76% bound to albumin.
2-5 L/kg; indicates extensive tissue distribution, particularly in adipose and brain.
Vd: 2.5–4.5 L/kg (large, indicating extensive tissue uptake).
Inhalation: 100% (administered as gas); no other relevant routes.
IV: 100% (only route used clinically).
No dose adjustment required for renal impairment; halothane is minimally excreted renally.
No dose adjustment required for renal impairment. Hemodialysis does not alter dosing. Use caution in severe renal failure due to propylene glycol vehicle if prolonged infusion.
Contraindicated in patients with Child-Pugh class B or C cirrhosis due to risk of hepatotoxicity; use with caution in mild impairment with reduced doses.
No specific adjustment for Child-Pugh class. However, prolonged effect may occur in severe hepatic impairment; reduce induction dose by 50% and titrate to effect.
Induction: 0.5-2% halothane in oxygen; maintenance: 0.3-1%. Dose based on response.
Induction: 0.2–0.6 mg/kg IV (max 40 mg). Age >10 years: use adult dosing. Neonates and infants: reduce dose to 0.3 mg/kg due to higher volume of distribution.
Reduce induction concentration to 0.5-1% and maintenance to 0.5% due to increased sensitivity and slower clearance.
Induction: 0.15–0.3 mg/kg IV (50% reduction of adult dose) due to decreased clearance and increased sensitivity. Use lower end of dosing range.
Halothane is associated with a risk of life-threatening hepatic injury, including fatal hepatic necrosis, primarily following repeated exposure or in patients with known hypersensitivity. It should be avoided in patients with a history of unexplained jaundice or fever after halothane administration.
Etomidate has been associated with mortality in children. It should not be used in children younger than 6 months of age. (This warning is included in the prescribing information based on FDA labeling; specific text may vary.)
Risk of hepatic necrosis (especially with repeated use); malignant hyperthermia; respiratory depression; hypotension; cardiac arrhythmias (including sensitization to catecholamines); increased intracranial pressure; requires trained personnel and monitoring; use caution in patients with hepatic disease.
Inhibition of adrenal steroidogenesis (adrenal suppression) due to blockade of 11-beta-hydroxylase, leading to decreased cortisol and aldosterone production; may persist for 12-24 hours after single dose,Myoclonic movements during induction (involuntary muscle contractions),Hypotension and bradycardia (less common than with other induction agents),Venous irritation and pain on injection (may be reduced by using larger veins)
Known hypersensitivity to halothane or other halogenated anesthetics; history of unexplained jaundice or fever after halothane administration; suspected or known hepatic injury from halogenated anesthetics; risk of malignant hyperthermia (including family history).
Hypersensitivity to etomidate,Patients with acute porphyria (may be porphyrinogenic)
No specific food interactions known, but fasting is required preoperatively to prevent aspiration pneumonitis caused by relaxation of the lower esophageal sphincter and loss of airway reflexes.
No specific food interactions are known. Etomidate is administered intravenously and does not have oral bioavailability. However, concurrent use of drugs that affect CYP3A4 (e.g., grapefruit juice) is not clinically significant due to IV route.
FDA Pregnancy Category C. First trimester: Increased risk of congenital anomalies (cleft palate, skeletal defects) in animal studies; avoid unless essential. Second and third trimesters: Prolonged exposure may cause neonatal respiratory depression, hypotonia, and thermoregulatory instability; risk of fetal hypoxia due to maternal hypotension.
Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may be associated with a slightly increased risk of congenital malformations, but data are limited. Risks to the fetus should be weighed against the benefits of maternal anesthesia. The drug is not recommended during pregnancy unless clearly needed, especially during organogenesis. In the second and third trimesters, etomidate may cause fetal central nervous system depression and respiratory depression if used near term.
Halothane is excreted in breast milk in low concentrations. M/P ratio not determined. Short-term use is considered compatible with breastfeeding; avoid prolonged or repeated exposure. Monitor infant for sedation and feeding difficulties.
It is unknown whether etomidate is excreted in human breast milk. The molecular weight (244.3) suggests potential excretion into milk. The milk-to-plasma ratio (M/P) has not been determined. Due to the short half-life (2–5 hours) and use as a single induction dose, transfer to the infant is likely minimal. However, caution is advised. The American Academy of Pediatrics classifies etomidate as 'compatible' with breastfeeding after a single dose, but data are insufficient for repeated or prolonged use. Infants should be monitored for sedation and respiratory depression.
Increased sensitivity to myocardial depression; reduce dose by 25-50% in pregnant patients. Monitor closely for hypotension. No specific pharmacokinetic adjustments required due to pregnancy, but consider decreased MAC (minimum alveolar concentration) in late pregnancy.
No specific dose adjustments are recommended for etomidate during pregnancy, but the dose should be individualized to achieve the desired level of anesthesia with the lowest effective dose. Physiologic changes in pregnancy (e.g., increased plasma volume, altered protein binding) may affect pharmacokinetics, but etomidate is rapidly redistributed and has a short duration of action. The standard induction dose of 0.2–0.6 mg/kg IV is used. Close monitoring of maternal and fetal status is advised. In cesarean section, lower doses may be considered to reduce fetal depression.
Halothane is a potent inhalational anesthetic with low blood-gas solubility, allowing rapid induction and emergence. It sensitizes the myocardium to catecholamines, increasing risk of arrhythmias, especially with epinephrine use. Halothane can cause hepatic necrosis, particularly with repeated exposure (halothane hepatitis). Avoid in patients with unexplained jaundice after prior halothane use. Use low concentrations with spontaneous ventilation to prevent respiratory depression.
Etomidate is an induction agent of choice in hemodynamically unstable patients due to minimal cardiovascular depression. Adrenal suppression occurs even after a single dose, manifesting as decreased cortisol and aldosterone synthesis via 11β-hydroxylase inhibition. Administer slowly over 30-60 seconds to reduce myoclonus and pain on injection. Use a lower dose (0.2-0.3 mg/kg IV) in elderly or debilitated patients. Etomidate is not recommended for rapid sequence intubation in septic shock due to risk of adrenal insufficiency; consider ketamine as alternative. Prolonged infusion is not advised due to propylene glycol vehicle and adrenal suppression.
Avoid food or drink for at least 6-8 hours before surgery to reduce aspiration risk.,Report any history of liver disease or allergic reactions to anesthesia.,You may experience shivering or nausea after waking up from anesthesia.,Do not drive or operate machinery for at least 24 hours after anesthesia.,Inform your doctor if you notice yellowing of skin or eyes, dark urine, or severe fatigue after surgery.
You may experience brief involuntary muscle movements during injection, which are usually harmless.,Tell your doctor if you have adrenal gland problems or are taking corticosteroids.,This drug may cause a temporary decrease in your body's ability to produce stress hormones.,Avoid driving or operating machinery until the effects of the medication have completely worn off.,Report any severe pain at the injection site or unusual weakness after the procedure.
No interactions on record
"Concurrent administration of etomidate and fluoxetine may potentiate the anesthetic and sedative effects, as fluoxetine inhibits CYP3A4 which is involved in the metabolism of etomidate, leading to increased etomidate plasma concentrations and prolonged recovery time. Additionally, both drugs can cause QTc interval prolongation, increasing the risk of torsades de pointes and other ventricular arrhythmias. Patients may experience enhanced central nervous system depression, respiratory depression, and hypotension."
"The combination of Promazine, a phenothiazine antipsychotic with strong alpha-adrenergic blocking activity, and Etomidate, a non-barbiturate hypnotic used for induction of anesthesia, can lead to an increased risk of hypotension due to additive vasodilatory effects. Promazine's alpha-1 receptor antagonism impairs compensatory vasoconstriction, while Etomidate suppresses adrenal cortisol synthesis, potentially blunting the stress response and further reducing hemodynamic stability. Clinically, this interaction may result in profound hypotension, especially in hypovolemic or elderly patients, requiring careful dose titration and monitoring."
"The coadministration of oxazepam, a benzodiazepine that enhances GABA-A receptor activity, with etomidate, a non-barbiturate anesthetic that also potentiates GABA-A receptor function, results in additive central nervous system (CNS) depression. This synergistic interaction can lead to excessive sedation, respiratory depression, hypotension, and prolonged recovery from anesthesia. Patients are at increased risk of apnea, hypoxia, and hemodynamic instability, particularly during induction and maintenance of anesthesia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLUOTHANE vs ETOMIDATE, answered by our medical review team.
FLUOTHANE is a General Anesthetic that works by Halothane enhances GABA-A receptor activity and inhibits NMDA receptors, leading to neuronal hyperpolarization and decreased excitability. It also potentiates glycine receptor function and disrupts synaptic transmission via interaction with voltage-gated sodium channels.. ETOMIDATE is a General Anesthetic that works by Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLUOTHANE and ETOMIDATE depend on the specific clinical indication. These are both General Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLUOTHANE is: Induction: 0.5-3% halothane in oxygen or nitrous oxide/oxygen; maintenance: 0.5-1.5%.. The standard adult dose of ETOMIDATE is: Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLUOTHANE and ETOMIDATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLUOTHANE is classified as Category C. FDA Pregnancy Category C. First trimester: Increased risk of congenital anomalies (cleft palate, skeletal defects) in animal studies; avoid unless essential. Second and third trime. ETOMIDATE is classified as Category C. Etomidate is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses higher than human doses. There are no adequate and well-co. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.